NASDAQ: KRYS

Krystal Biotech (KRYS) Stock Analysis & Forecast

Nov 13 close

$305.23−0.45 (−0.1%)

Gekko Brief

AI summaryNov 9 close

Krystal Biotech's week centers on third-quarter results and the market reaction to them. The company reported VYJUVEK revenue of $127.3 million, up 30% year-over-year, diluted EPS of $2.05 against a consensus estimate of $1.79, and $1.2 billion in cash, while the board authorized a $400 million share repurchase program over two years. Despite the beat and buyback news, the stock fell 8.2% on the reaction, which one analyst characterized as "overblown." Separately, Citigroup and TD Cowen each maintained Buy ratings while trimming price targets to $412 and $380 respectively, and the stock carries a broader "Moderate Buy" consensus from covering analysts.

The stock closed at $303.06, up 0.7%, sitting between its 50-day average of $331.52 and 200-day average of $309.12, with one-month and three-month returns of -8.6% and -7.3% respectively against a one-year return of 51.6%. The GekkoIndex reads 66.1, placing it in the Accumulation zone. Price sits 28.9% below Gekko Fair Value of $426.17.

The next earnings date falls on 16 February 2027, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 10.6% return over five years, though gains occurred in only 2 of those years. The consensus price target stands at $388.22, implying 28.1% upside from current levels.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Krystal Biotech price vs fair value

$412.15$305.23Nov ’25May ’26Nov ’26
Close $305.23200-day averageGekko Fair Value $412.15

Krystal Biotech quick facts

Market cap
$9.05B
P/E ratio
41.5
Forward P/E
39.8
EPS, TTM
$7.36
Revenue, TTM
$470.0M
Profit margin
47.9%
Dividend yield
—
Beta
0.65
Volume
109,685 avg 312,921
1-year return
+50.3%
Typical daily move
±4.1%
Typical 20-day move
±7.8%
50-day average
$326.77
200-day average
$309.71
Next earnings
Feb 16 before open
Shares outstanding
29.63M
52-week range
$198.02$382.54

Krystal Biotech swing-trade checklist

Krystal Biotech scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $305.23 sits between the 50-day ($326.77) and 200-day ($309.71) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    62.5, Accumulation

    Reading 62.5 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    25.9% below

    Price is 25.9% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 93 days

    Next report Feb 16, 2027, 93 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +13.5% on average

    From this point in the calendar, the next 20 trading days averaged +13.5% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Krystal Biotech stock chart and price history

Krystal Biotech closed at $305.23 on Nov 13, 2026, +50.3% over the past year, inside a 52-week range of $198.02 to $382.54.

Close50-day average200-day averageVolume
Krystal Biotech share price, past year, with 50-day and 200-day moving averages and volume$150$200$250$350DecJan 2026FebMarAprMayJunJulAugSepOctNov305.23

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−7.5%
3 months
−9.1%
6 months
−0.3%
1 year
+50.3%
The full KRYS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KRYS in Gekko

Follow Krystal Biotech through every session

Put KRYS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track KRYS in GekkoFree for 7 days. No credit card required.

About Krystal Biotech

Krystal Biotech works on gene therapies designed to be given more than once, aimed at rare and severe diseases that currently have few treatment options. Its furthest-along candidate, beremagene geperpavec, is in Phase III testing for dystrophic epidermolysis bullosa, a skin condition, and this program is the one most associated with the company.

Beyond that lead candidate, Krystal Biotech runs a broader pipeline at different stages. KB105 and KB301 are in Phase I/II trials, treating autosomal recessive congenital ichthyosis and aiming to address skin wrinkling and damage respectively. KB407 for cystic fibrosis and KB104 for Netherton syndrome remain in preclinical testing, while earlier-stage work includes KB5xx candidates for chronic skin conditions and several KB3xx programs focused on dermatological aesthetic issues.

Krystal Biotech was founded in 2015 and operates out of Pittsburgh, Pennsylvania. Its shares are listed on the NASDAQ under the ticker KRYS.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
krystalbio.com

Krystal Biotech GekkoIndex: the smart money zone

Krystal Biotech’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.5, in the Accumulation zone, down 4.9 points over five sessions.

010062.5Accumulation

Down 4.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying20−1.7%−1.5%+25.2%+34.0%
Accumulation (current zone)221+2.9%+3.9%+4.8%+10.8%
Neutral4090.0%+0.8%+2.3%+6.2%
Distribution51−0.3%+1.3%+2.6%+9.1%
Selling1Too few readings yet

Average KRYS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the KRYS price, zone by zone.Track KRYS in Gekko

Is Krystal Biotech stock overvalued? Gekko Fair Value

Krystal Biotech trades 25.9% below Gekko Fair Value of $412.15, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Krystal Biotech shares are worth, recalculated every trading day.

$412.15

Gekko Fair Value, Nov 14, 2026

25.9% Undervalued

At the end of Aug 2026 the price was 16.2% below the estimate.

Gekko Fair ValueShare price, month end
$412$305Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open KRYS in Gekko

Krystal Biotech insider and Congress trading

No open-market insider purchases were filed for Krystal Biotech, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for KRYS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every KRYS insider filing, plotted on the chart in Gekko.Open KRYS in Gekko

Congress trades last 90 days

No trades in KRYS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for KRYS, plotted on the chart in Gekko.Open KRYS in Gekko

Buybacks

Krystal Biotech has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$108K
As a share of market cap
0.00%

From company filings.

Krystal Biotech earnings: next date and track record

Krystal Biotech reports on Feb 16, 2027, before the open (93 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±8.8%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+16.5%Feb ’25−15.7%May ’25−12.5%Aug ’25+2.9%Nov ’25+2.5%Feb ’26+7.0%May ’26−4.8%Aug ’26−8.2%Nov ’26

Last earnings call, Nov 2, 2026 AI summary

What they said
KRYS reported Q3 revenue of $127.3M for VYJUVEK, up 30% YoY, with diluted EPS of $2.05 and $1.2B in cash. Cumulative VYJUVEK revenues since launch reached ~$1.1B. International revenue hit $32M with expansion across Germany, France, and Japan. The board authorized a $400M share repurchase program over 2 years. Gorlin syndrome trial showed encouraging tumor regression data.
Guidance
Management expects to deploy $400M in buybacks over 2 years. Pipeline clinical readouts were delayed but management indicated results expected in upcoming months. International pricing negotiations ongoing across additional markets.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 2, 2026$2.05
est $1.79
+14.5%$127.3M
est $125.8M
+1.2%−8.2%
Aug 3, 2026$1.79
est $1.70
+5.3%$119.2M
est $120.9M
−1.4%−4.8%
May 4, 2026$1.83
est $1.46
+25.3%$116.4M
est $112.1M
+3.8%+7.0%
Feb 17, 2026$1.70
est $1.62
+4.9%$107.1M
est $105.3M
+1.7%+2.5%
Nov 3, 2025$2.66
est $1.12
+137.5%$97.80M
est $105.3M
−7.1%+2.9%
Aug 4, 2025$1.29
est $1.08
+19.4%$96.04M
est $95.41M
+0.7%−12.5%
May 6, 2025$1.20
est $1.03
+16.1%$88.18M
est $106.0M
−16.8%−15.7%
Feb 19, 2025$1.53
est $1.85
−17.4%$91.14M
est $91.35M
−0.2%+16.5%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Krystal Biotech stock forecast and analyst price targets

Analysts’ average 12-month price target for Krystal Biotech is $388.22, +27.2% from the last close, from 6 firms rating the stock in the last 90 days.

$388.22consensus 12-month target, +27.2% from the last close
Low $361High $441
Buy6
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 6RBC CapitalBuy, reiterated$375+22.9%
Nov 3CitiBuy, maintained$412+35.0%
Nov 3TD CowenBuy, maintained$380+24.5%
Nov 2RBC CapitalBuy, reiterated$375+22.9%
Nov 2H.C. WainwrightBuy, reiterated$361+18.3%
+4.8%average 20-day move after past Accumulation readings
+13.5%average move over the next 20 trading days in the last 5 years
±4.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Krystal Biotech seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Krystal Biotech averaged +13.5% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+48.2%2021−4.4%2022+11.5%2023−7.8%2024+17.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.7%1 of 5
Next 10 trading days+15.6%3 of 5
Next 15 trading days+11.9%2 of 5
Next 20 trading days+13.5%3 of 5
Next 30 trading days+15.7%3 of 5

For scale, KRYS’s typical 20-trading-day move in either direction is about 7.8%.

Krystal Biotech market cap and key statistics

Krystal Biotech’s market cap is $9.05B, with a P/E ratio of 41.5 and revenue of $470.0M over the last twelve months.

Valuation

Market cap
$9.05B
P/E ratio
41.5
Forward P/E
39.8
EPS, TTM
$7.36
Gekko Fair Value
$412.15

Trading

Volume
109,685
Avg volume, 20 days
312,921
52-week high
$382.54
52-week low
$198.02
Shares outstanding
29.63M

Financials

Revenue, TTM
$470.0M
Profit margin
47.9%
Return on equity
17.5%
Quarterly earnings growth, YoY
−22.9%

Risk and income

Beta
0.65
Typical daily move
±4.1%
Typical 20-day move
±7.8%

Krystal Biotech stock news this week

Coverage of Krystal Biotech this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.

News sentiment neutral

Krystal Biotech peers

Krystal Biotech’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Krystal Biotech stock FAQ

What is Krystal Biotech’s market cap?

Krystal Biotech’s market cap is $9.05B at the Nov 13, 2026 close of $305.23, with 29.63M shares outstanding. The shares trade on a P/E ratio of 41.5.

What is the Krystal Biotech stock forecast?

The consensus analyst 12-month price target for Krystal Biotech is $388.22, +27.2% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Krystal Biotech stock overvalued or undervalued?

On Gekko’s estimate Krystal Biotech is undervalued: the Nov 13, 2026 close of $305.23 is 25.9% below Gekko Fair Value of $412.15. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Krystal Biotech report earnings next?

Krystal Biotech is expected to report on Feb 16, 2027, before the market opens (93 days away). Analysts expect earnings of $2.04 per share on revenue of $134.0M. Krystal Biotech beat the earnings estimate in 7 of its last 8 reports, moving 8.8% on average across the report.

What is Krystal Biotech’s 52-week high and low?

Krystal Biotech’s 52-week high is $382.54 and its 52-week low is $198.02; it closed at $305.23 on Nov 13, 2026, +50.3% over the past year.

Is Krystal Biotech stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Krystal Biotech the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.